Late cognitive and adaptive outcomes of patients with neuroblastoma‐associated opsoclonus‐myoclonus‐ataxia‐syndrome: A report from the Children's Oncology Group
Fuente:
Wiley Open Access
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Artículo Open Access |
| Publicado: |
Wiley
2024
|
| Materias: | |
| Acceso en línea: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1867011725446873088 |
|---|---|
| author | Prerna Kumar Victoria W. Willard Leanne Embry Arlene Naranjo Brian LaBarre Katherine K. Matthay Pedro A. de Alarcon |
| author_facet | Prerna Kumar Victoria W. Willard Leanne Embry Arlene Naranjo Brian LaBarre Katherine K. Matthay Pedro A. de Alarcon Prerna Kumar Victoria W. Willard Leanne Embry Arlene Naranjo Brian LaBarre Katherine K. Matthay Pedro A. de Alarcon |
| collection | Wiley Open Access |
| contents | Late cognitive and adaptive outcomes of patients with neuroblastoma‐associated opsoclonus‐myoclonus‐ataxia‐syndrome: A report from the Children's Oncology Group Prerna Kumar Victoria W. Willard Leanne Embry Arlene Naranjo Brian LaBarre Katherine K. Matthay Pedro A. de Alarcon Pediatric Blood & Cancer Abstract Background Opsoclonus‐myoclonus‐ataxia syndrome (OMAS) is a rare autoimmune disorder of the nervous system presenting with abnormal eye and limb movements, altered gait, and increased irritability. Two to four percent of children diagnosed with neuroblastoma have neuroblastoma‐associated OMAS (NA‐OMAS). These children typically present with non‐high‐risk neuroblastoma that is cured with surgery, with or without chemotherapy. Despite excellent overall survival, patients with NA‐OMAS can have significant persistent neurological and developmental issues. Objective This study aimed to describe long‐term neurocognitive and adaptive functioning of patients with NA‐OMAS treated with multimodal therapy, including intravenous immunoglobulin (IVIG) on Children's Oncology Group (COG) protocol ANBL00P3. Methods Of 53 children enrolled on ANBL00P3, 25 submitted evaluable neurocognitive data at diagnosis and at least one additional time point within 2 years and were included in the analyses. Adaptive development was assessed via the Vineland Adaptive Behavior Scale, and validated, age‐appropriate measures of intellectual function were also administered. Results Twenty‐one of the 25 patients in this cohort ultimately received IVIG. Descriptive spaghetti plots suggest that this cohort demonstrated stable long‐term cognitive functioning and adaptive development over time. This cohort also demonstrated decreased OMAS scores over time consistent with improved OMAS symptoms. Conclusions While statistical significance is limited by small sample size and loss to follow‐up over 10 years, findings suggest stable long‐term cognitive and adaptive functioning over time in this treated cohort. 10.1002/pbc.31039 http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| doi_str_mv | 10.1002/pbc.31039 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_pbc_31039 |
| institution | Wiley Open Access |
| license_str_mv | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| publishDate | 2024 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Late cognitive and adaptive outcomes of patients with neuroblastoma‐associated opsoclonus‐myoclonus‐ataxia‐syndrome: A report from the Children's Oncology Group Prerna Kumar Victoria W. Willard Leanne Embry Arlene Naranjo Brian LaBarre Katherine K. Matthay Pedro A. de Alarcon Pediatric Blood & Cancer Late cognitive and adaptive outcomes of patients with neuroblastoma‐associated opsoclonus‐myoclonus‐ataxia‐syndrome: A report from the Children's Oncology Group Prerna Kumar Victoria W. Willard Leanne Embry Arlene Naranjo Brian LaBarre Katherine K. Matthay Pedro A. de Alarcon Pediatric Blood & Cancer Abstract Background Opsoclonus‐myoclonus‐ataxia syndrome (OMAS) is a rare autoimmune disorder of the nervous system presenting with abnormal eye and limb movements, altered gait, and increased irritability. Two to four percent of children diagnosed with neuroblastoma have neuroblastoma‐associated OMAS (NA‐OMAS). These children typically present with non‐high‐risk neuroblastoma that is cured with surgery, with or without chemotherapy. Despite excellent overall survival, patients with NA‐OMAS can have significant persistent neurological and developmental issues. Objective This study aimed to describe long‐term neurocognitive and adaptive functioning of patients with NA‐OMAS treated with multimodal therapy, including intravenous immunoglobulin (IVIG) on Children's Oncology Group (COG) protocol ANBL00P3. Methods Of 53 children enrolled on ANBL00P3, 25 submitted evaluable neurocognitive data at diagnosis and at least one additional time point within 2 years and were included in the analyses. Adaptive development was assessed via the Vineland Adaptive Behavior Scale, and validated, age‐appropriate measures of intellectual function were also administered. Results Twenty‐one of the 25 patients in this cohort ultimately received IVIG. Descriptive spaghetti plots suggest that this cohort demonstrated stable long‐term cognitive functioning and adaptive development over time. This cohort also demonstrated decreased OMAS scores over time consistent with improved OMAS symptoms. Conclusions While statistical significance is limited by small sample size and loss to follow‐up over 10 years, findings suggest stable long‐term cognitive and adaptive functioning over time in this treated cohort. 10.1002/pbc.31039 http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| title | Late cognitive and adaptive outcomes of patients with neuroblastoma‐associated opsoclonus‐myoclonus‐ataxia‐syndrome: A report from the Children's Oncology Group |
| topic | Pediatric Blood & Cancer |
| url | https://onlinelibrary.wiley.com/doi/10.1002/pbc.31039 |